TMCnet News

Research and Markets: PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 for the $10 Billion Industry
[September 25, 2014]

Research and Markets: PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 for the $10 Billion Industry


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/7vck6x/pharmapoint) has announced the addition of the "PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023" report to their offering.

The 2013 base-year market sales for asthma pharmaceuticals in the US were around $10.1 billion

As in the global market, this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of numerous SABA, ICS, and ICS/LABA products over the forecast period, will be offset by eight pipeline product launches, seven of which are targeted biologics.

Scope

- Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficay profiles as well as a SWOT analysis.



- Sales forecast for the top drugs in the US from 2013-2023.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Asthma market.


Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

  • Etiology
  • Pathophysiology
  • Prognosis (News - Alert)
  • Quality of Life
  • Symptoms

4 Disease Management

  • Diagnosis
  • Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
  • Clinical Practice

5 Competitive Assessment

  • Flovent (fluticasone propionate)
  • Pulmicort (Budesonide)
  • Other Inhaled Corticosteroids
  • Long-Acting Beta-Agonists
  • Advair (fluticasone propionate/salmeterol xinafoate)
  • Symbicort (Budesonide/formoterol fumarate)
  • Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
  • Dulera (mometasone furoate/formoterol fumarate)
  • Singulair (montelukast)
  • Other Leukotriene Modifiers
  • Short-Acting Beta-Agonists
  • Targeted Therapies
  • Xolair (omalizumab)
  • Spiriva (tiotropium bromide)

6 Unmet Need and Opportunity

  • Personalized Therapies to Control Severe Asthma
  • Better Patient Compliance
  • Lower Cost of Asthma Medications
  • Proper Diagnosis of Asthma in Children

7 Pipeline Assessment

  • Fluticasone furoate
  • Cinquil (reslizumab)
  • Bosatria (mepolizumab)
  • Lebrikizumab
  • Benralizumab
  • Dupilumab
  • Quilizumab
  • Tralokinumab

8 Market Outlook

  • Forecast
  • Key Events
  • Drivers and Barriers

9 Appendix

For more information visit http://www.researchandmarkets.com/research/7vck6x/pharmapoint


[ Back To TMCnet.com's Homepage ]